Reported Earlier, Renalytix Fights Nasdaq Delisting With Strategic Plan, Trading Temporarily Safe
Reported Earlier, Renalytix Fights Nasdaq Delisting With Strategic Plan, Trading Temporarily Safe
Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the
Renalytix股份有限公司（納斯達克股票代碼：RNLX）（倫敦證券交易所股票代碼：RENX）宣佈，已正式向納斯達克聽證會申請提交聽證請求（以下簡稱“聽證會”），該請求目前已暫停
Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX."
Renalytix股份有限公司（納斯達克股票代碼：RNLX）（倫敦證券交易所股票代碼：RENX）宣佈，已正式向納斯達克聽證會申請提交聽證請求（以下簡稱“聽證會”），此請求現已暫停公司證券的掛牌交易，直到聽證會作出決定爲止。在聽證會作出決定前的整個聽證程序期間，該公司的美國存托股份（以下簡稱“ADS”）將繼續在納斯達克全球市場上以“RNLX”標的繼續交易。
At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Company's plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Company's ADSs are delisted, it could be more difficult to buy or sell the Company's ADSs or to obtain accurate quotations, and the price of the Company's ADSs could suffer a material decline. Delisting could also impair the Company's ability to raise capital.
在聽證會上，公司打算提出一項戰略計劃，以恢復符合適用的納斯達克上市要求。但是，無法保證公司的計劃將被委員會接受，如果被接受，公司將能否符合適用的納斯達克上市要求。如果公司的 ADS 被退市，可能更難買入或賣出公司的 ADS，或者獲得準確的行情報價，公司的 ADS 價格可能會遭受實質性下跌。退市也可能會影響公司籌集資本的能力。
As previously disclosed, on June 25, 2024, the Company received written notice on June 21, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has been out of compliance with Nasdaq's minimum closing bid price requirement, as set forth in Nasdaq Listing Rule 5450(a)(1), for the Company's ADSs and the requirement to maintain a minimum market value of listed securities of $50,000,000 for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). Accordingly, the Company has submitted the Nasdaq hearing request, which has automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the authority to grant an extension not to exceed 180 days from the date of the Nasdaq delisting notice.
正如先前披露的那樣，2024年6月25日，公司收到了納斯達克股票市場有限責任公司的上市資格部門（"納斯達克"）的書面通知，通知公司其未達到納斯達克的最低收盤要求價要求，如納斯達克上市規則5450(a)(1)所述，對於公司的 ADS 和維持上市的最低證券市值要求爲5,000萬美元，如納斯達克上市規則5450(b)(2)(A)所述。因此，公司已提交了納斯達克聽證請求，這自動暫停了任何停牌或退市行動，直到聽證會和委員會聽證後授予的任何額外延期期限到期。在這方面，根據納斯達克上市規則，委員會有權授予不超過從納斯達克退市通知之日起180天的延期。
譯文內容由第三人軟體翻譯。